A phase II trial of bisantrene (CL216,942) in refractory epithelial ovarian cancer.
Twenty-three evaluable patients with refractory epithelial ovarian cancer were treated with bisantrene (CL216,942). The drug was given as a single-dose injection every 3 weeks. One patient (4%) showed a partial response. The compound thus has limited activity against this malignancy.
D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000873:Anthracenes; C031404:bisantrene